Core Insights - LifeMD has launched a subscription program for Novo Nordisk's Wegovy® (semaglutide), providing significant annual savings for patients [1][2] - The subscription model enhances patient access to branded GLP-1 therapy and supports treatment adherence [2][3] Company Overview - LifeMD is a leading provider of virtual primary care services, offering telemedicine and access to laboratory and pharmacy services across more than 200 conditions [5] - The company has a vertically integrated digital care platform and a 50-state affiliated medical group [5] Collaboration Details - The Wegovy® subscription program is an extension of LifeMD's collaboration with Novo Nordisk, which has evolved from an initial pharmacy integration to a comprehensive commercial partnership [3] - LifeMD is recognized as a telehealth provider on both the NovoCare® and Wegovy® websites, highlighting the strength of their relationship [3] Patient Benefits - Patients enrolled in the Wegovy® program through LifeMD can save up to $1,200 annually for injectable formulations and $600 for oral therapy [2] - The program offers a comprehensive care experience, including virtual visits, ongoing clinical oversight, diagnostic testing, and simplified billing [4]

Core Insights - Novo Nordisk is enhancing patient access and affordability for its weight management medication, Wegovy®, with over 55 million people in the U.S. having coverage for such medicines, and 90% of Wegovy® patients with coverage paying between $0 to $25 monthly [1] - The introduction of NovoCare® Pharmacy allows cash-paying patients to receive Wegovy® prescriptions directly at home, fulfilling orders through CenterWell Pharmacy, which has received multiple awards for customer satisfaction [1] - NovoCare® Pharmacy ensures patients receive authentic, FDA-approved Wegovy®, mitigating risks associated with the compounding marketplace, and will soon update savings offers for cash-paying patients using traditional retail pharmacies [1] Company Overview - Novo Nordisk is a leading global healthcare company with over 100 years of experience in developing innovative medicines for diabetes and other chronic diseases, including obesity [14] - The company operates U.S. headquarters in New Jersey and has commercial, production, and research facilities across seven states and Washington D.C., employing approximately 8,000 people [14] Product Information - Wegovy® (semaglutide) is an injectable prescription medicine used alongside a reduced-calorie diet and increased physical activity, specifically for weight management [3] - It is not recommended for use in children under 12 years of age and should not be used with other semaglutide-containing products or GLP-1 receptor agonists [3] Safety and Support - Wegovy® may cause serious side effects, including potential thyroid tumors, pancreatitis, and kidney problems, necessitating careful monitoring and communication with healthcare providers [7][12] - NovoCare® Pharmacy provides additional support services, including benefit verification, refill reminders, and access to live case managers to assist patients [1]